Recently published four-arm target trial which included 283 998 patients compared effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors and sulfonylureas
Those with PCOS may be more likely to experience this type of cycle change, which is also in line with previous research where GLP-1 medications have shown some promise for improving menstrual cycle regularity in women with PCOS
As of March 2026, retatrutide is investigational
That answer is coming, but it is not here yet
This review aims to put these hypotheses into perspective with the available data on GLP-1 release in healthy and type 2 diabetic participants, and to address common differences of opinion and some potential misconceptions in the interpretation of commonly quoted landmark publications
Men over 40 typically see: Faster initial scale movement (58 lbs in weeks 14 versus 25 lbs for women) More linear weekly loss patterns Less hormonal water retention masking results Stronger early appetite suppression response Women over 40 typically see: Slower initial scale loss but more dramatic body composition change relative to scale weight Greater week-to-week scale fluctuation due to cycle and hormonal factors Faster muscle and waist response when protein intake is adequate More pronounced GI side effects at the same per-kilogram dose The most important difference is in the metrics that matter
